Ozempic and kidney health: what the FLOW trial means for you
For years, doctors prescribed GLP-1 medications primarily for blood sugar control and, more recently, for weight loss. But something unexpected kept showing up in the data: people taking these drugs had fewer kidney problems. The FLOW trial, published in the New England Journal of Medicine in 2024, confirmed what many researchers suspected — semaglutide doesn’t just spare the kidneys, it actively protects them. This makes it one of the most promising diabetes kidney medications available today. ...